Dihomogammalinolenic acid (20:3 omega 6) is more anti-aggregatory than eicosapentaenoic (20:5 omega 3) in a platelet-endothelial cell mixture.
The effect of 20:3 omega 6, the precursor of 1 series prostaglandins was to inhibit platelet aggregation more strongly than either 20:5 omega 3, the precursor of 3 series prostaglandins or 20:3 omega 3 which is not a substrate of prostaglandin synthetase. When platelets and dissociated endothelial cells were pretreated with 20:3 omega 6, platelet aggregation in the presence of endothelial cells was much more inhibited than after 20:5 omega 3 pretreatment.
D015126:8,11,14-Eicosatrienoic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D002449:Cell Aggregation / Q000187:drug effects*; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004537:Eicosanoic Acids / Q000494:pharmacology*; D015118:Eicosapentaenoic Acid; D004727:Endothelium / Q000187:drug effects / Q000502:physiology; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005260:Female; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011247:Pregnancy; D013329:Structure-Activity Relationship; D013917:Thrombin / Q000494:pharmacology; D014470:Umbilical Cord / Q000187:drug effects / Q000502:physiology
D004537:Eicosanoic Acids; D005231:Fatty Acids, Unsaturated; D003094:Collagen; D015118:Eicosapentaenoic Acid; D013917:Thrombin; D015126:8,11,14-Eicosatrienoic Acid